Albemarle (NYSE:ALB) was upgraded by investment analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a research note issued on Monday, Marketbeat Ratings reports. The firm presently has a $133.51 price target on the specialty chemicals company’s stock, up from their previous price target of $131.72. Robert W. Baird’s price objective suggests a potential downside of 1.42% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. Jefferies Group reaffirmed a “buy” rating on shares of Albemarle in a research note on Tuesday, October 24th. Royal Bank of Canada lifted their target price on shares of Albemarle from $149.00 to $155.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. Goldman Sachs Group cut shares of Albemarle from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $139.66 to $142.00 in a research note on Friday, October 6th. Zacks Investment Research cut shares of Albemarle from a “buy” rating to a “hold” rating in a research note on Tuesday, December 19th. Finally, Oppenheimer lifted their target price on shares of Albemarle from $133.00 to $157.00 and gave the stock an “outperform” rating in a research note on Monday, October 16th. Ten analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Albemarle has a consensus rating of “Buy” and an average target price of $128.38.

Shares of Albemarle (ALB) opened at $135.44 on Monday. Albemarle has a one year low of $89.09 and a one year high of $144.99. The stock has a market cap of $14,970.00, a price-to-earnings ratio of 48.37, a P/E/G ratio of 1.73 and a beta of 1.69. The company has a quick ratio of 1.56, a current ratio of 2.11 and a debt-to-equity ratio of 0.35.

Albemarle (NYSE:ALB) last announced its earnings results on Wednesday, November 8th. The specialty chemicals company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.01. Albemarle had a net margin of 30.07% and a return on equity of 11.61%. The company had revenue of $755.00 million for the quarter, compared to analysts’ expectations of $732.19 million. During the same quarter in the previous year, the company posted $0.91 EPS. The firm’s quarterly revenue was up 15.4% on a year-over-year basis. equities analysts expect that Albemarle will post 4.46 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of ALB. Pacer Advisors Inc. raised its holdings in Albemarle by 9.0% in the 2nd quarter. Pacer Advisors Inc. now owns 2,118 shares of the specialty chemicals company’s stock valued at $224,000 after buying an additional 174 shares during the period. Neuberger Berman Group LLC raised its holdings in Albemarle by 43.5% in the 2nd quarter. Neuberger Berman Group LLC now owns 13,701 shares of the specialty chemicals company’s stock valued at $1,446,000 after buying an additional 4,154 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in Albemarle in the 2nd quarter valued at about $386,000. Commerce Bank purchased a new stake in Albemarle in the 2nd quarter valued at about $222,000. Finally, Oppenheimer Asset Management Inc. raised its holdings in Albemarle by 4.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 7,570 shares of the specialty chemicals company’s stock valued at $799,000 after buying an additional 295 shares during the period. Hedge funds and other institutional investors own 87.99% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/robert-w-baird-upgrades-albemarle-alb-to-outperform/1800960.html.

Albemarle Company Profile

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Analyst Recommendations for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle and related companies with Analyst Ratings Network's FREE daily email newsletter.